MRK · News · 20260908N
Keytruda Patent Expiration Outlook
Merck & Co., Inc. · 2026-09-08 · Importance 50 · Surprise 24 · In source text
Keytruda remains Merck’s principal growth driver, supporting recent sales momentum and investor interest. Third-party reporting warns that biosimilar competition could intensify around the drug’s expected 2028 patent cliff, creating a material threat to Merck’s oncology franchise. Merck’s pipeline and newer products are being positioned as potential offsets to the eventual erosion of Keytruda sales.
Key facts
- Reports warn that Keytruda's biosimilar countdown is getting louder and reference a 2028 patent-related timeline (2028 patent cliff). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | contingent | — | Reports warn that Keytruda's biosimilar countdown is getting louder and reference a 2028 patent-related timeline (2028 patent cliff). |